Top-Rated StocksTop-RatedNASDAQ:MIRM Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis $43.33 +2.96 (+7.33%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$39.70▼$44.7050-Day Range$24.03▼$43.3352-Week Range$23.14▼$44.70Volume2.41 million shsAverage Volume741,442 shsMarket Capitalization$2.04 billionP/E RatioN/ADividend YieldN/APrice Target$53.64 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Mirum Pharmaceuticals alerts: Email Address Mirum Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.17 Rating ScoreUpside/Downside23.8% Upside$53.64 Price TargetShort InterestBearish17.34% of Shares Sold ShortDividend StrengthN/ASustainability-1.69Upright™ Environmental ScoreNews Sentiment0.61Based on 9 Articles This WeekInsider TradingSelling Shares$1.18 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.66) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.85 out of 5 starsMedical Sector142nd out of 936 stocksPharmaceutical Preparations Industry58th out of 436 stocks 3.6 Analyst's Opinion Consensus RatingMirum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMirum Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Mirum Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.34% of the outstanding shares of Mirum Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMirum Pharmaceuticals has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Mirum Pharmaceuticals has recently increased by 14.27%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMirum Pharmaceuticals does not currently pay a dividend.Dividend GrowthMirum Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMirum Pharmaceuticals has received a 61.01% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mirum Pharmaceuticals is -1.69. Previous Next 2.6 News and Social Media Coverage News SentimentMirum Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Mirum Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest18 people have searched for MIRM on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat FollowsOnly 14 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mirum Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,180,156.00 in company stock.Percentage Held by Insiders22.87% of the stock of Mirum Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Mirum Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($1.66) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mirum Pharmaceuticals is -11.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mirum Pharmaceuticals is -11.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMirum Pharmaceuticals has a P/B Ratio of 8.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Mirum Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Mirum Pharmaceuticals Stock (NASDAQ:MIRM)Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Read More MIRM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MIRM Stock News HeadlinesJuly 4, 2024 | insidertrades.comJolanda Howe Sells 375 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockJune 27, 2024 | insidertrades.comPamela Vig Sells 30,559 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 26 at 6:31 PM | markets.businessinsider.comBuy Rating Affirmed for Mirum Pharmaceuticals Amidst Label Expansion and Positive EU AuthorizationJuly 26 at 12:44 AM | markets.businessinsider.comBuy Rating Affirmed for Mirum Pharmaceuticals on Market Expansion and Robust Pipeline ProspectsJuly 25 at 2:43 PM | msn.comMirum granted FDA label expansion for lead drug in liver diseaseJuly 25 at 9:41 AM | finance.yahoo.comMirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and OlderJuly 25 at 7:00 AM | americanbankingnews.comMirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 52-Week High at $40.75July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 21, 2024 | americanbankingnews.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $53.64 Consensus PT from AnalystsJuly 17, 2024 | americanbankingnews.comMirum Pharmaceuticals (NASDAQ:MIRM) Hits New 1-Year High at $40.00July 17, 2024 | seekingalpha.comBullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic AcquisitionJune 17, 2024 | benzinga.comMirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage StudiesJune 17, 2024 | businesswire.comMirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC StudiesJune 16, 2024 | businesswire.comMirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024June 10, 2024 | businesswire.comMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2024 | businesswire.comMirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 31, 2024 | businesswire.comMirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and OlderSee More Headlines Receive MIRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/27/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MIRM CUSIPN/A CIK1759425 Webmirumpharma.com Phone(650) 667-4085FaxN/AEmployees140Year FoundedN/APrice Target and Rating Average Stock Price Target$53.64 High Stock Price Target$68.00 Low Stock Price Target$39.00 Potential Upside/Downside+23.8%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-163,410,000.00 Net Margins-69.67% Pretax Margin-70.16% Return on Equity-56.46% Return on Assets-19.61% Debt Debt-to-Equity Ratio1.31 Current Ratio3.68 Quick Ratio3.47 Sales & Book Value Annual Sales$186.37 million Price / Sales10.96 Cash FlowN/A Price / Cash FlowN/A Book Value$5.33 per share Price / Book8.13Miscellaneous Outstanding Shares47,130,000Free Float36,354,000Market Cap$2.04 billion OptionableOptionable Beta1.15 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Christopher Peetz (Age 45)CEO & Director Comp: $1.31MMr. Peter Radovich M.B.A. (Age 46)Ph.D., COO & President Comp: $881.8kMr. Eric H. Bjerkholt M.B.A. (Age 64)Chief Financial Officer Comp: $600.4kDr. Pamela Vig Ph.D. (Age 53)Chief Scientific Officer Comp: $678.2kAndrew McKibbenVice President of Investor Relations and FinanceMr. Paul K. RossChief Compliance OfficerMs. Erin Campany (Age 56)Senior Vice President of Human Resources Ms. Lara Longpre MBA (Age 54)MSC, Chief Development Officer Comp: $678.2kMs. Vinita P. KumarSenior vice President of QualityDr. Jean-Luc Girardet Ph.D.Senior Vice President of Technical OperationsMore ExecutivesKey CompetitorsIntercept PharmaceuticalsNASDAQ:ICPTAvid BioservicesNASDAQ:CDMOUrovant SciencesNASDAQ:UROVCymaBay TherapeuticsNASDAQ:CBAYNGM BiopharmaceuticalsNASDAQ:NGMView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 46,506 shares on 7/26/2024Ownership: 0.303%AlphaCentric Advisors LLCSold 30,000 shares on 7/26/2024Ownership: 0.136%Secure Asset Management LLCBought 3,630 shares on 7/24/2024Ownership: 0.097%Hennion & Walsh Asset Management Inc.Bought 41,236 shares on 7/20/2024Ownership: 0.222%Values First Advisors Inc.Sold 1,654 shares on 7/19/2024Ownership: 0.042%View All Insider TransactionsView All Institutional Transactions MIRM Stock Analysis - Frequently Asked Questions How have MIRM shares performed this year? Mirum Pharmaceuticals' stock was trading at $29.52 at the beginning of 2024. Since then, MIRM stock has increased by 46.8% and is now trading at $43.33. View the best growth stocks for 2024 here. How were Mirum Pharmaceuticals' earnings last quarter? Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) released its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.14. The company had revenue of $69.22 million for the quarter, compared to the consensus estimate of $69.71 million. Mirum Pharmaceuticals had a negative net margin of 69.67% and a negative trailing twelve-month return on equity of 56.46%. When did Mirum Pharmaceuticals IPO? Mirum Pharmaceuticals (MIRM) raised $75 million in an initial public offering on Thursday, July 18th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers. Who are Mirum Pharmaceuticals' major shareholders? Top institutional shareholders of Mirum Pharmaceuticals include Raymond James & Associates (0.31%), Bank of New York Mellon Corp (0.30%), Hennion & Walsh Asset Management Inc. (0.22%) and AlphaCentric Advisors LLC (0.14%). Insiders that own company stock include Niall O'donnell, James E Flynn, Patrick J Heron, Christopher Peetz, Lara Longpre, Peter Radovich, Pamela Vig, Jolanda Howe, Ian Clements and Michael G Grey. View institutional ownership trends. How do I buy shares of Mirum Pharmaceuticals? Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Mirum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB) and Sorrento Therapeutics (SRNE). This page (NASDAQ:MIRM) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
